|Budget Amount *help
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|Outline of Final Research Achievements
Giant cell tumors of bone (GCTB) is a locally aggressive neoplasm of bone, with a propensity for recurrence.RANK ligand secreted by the immature osteoblast-like stromal cells of these tumors induce the formation of osteoclast-like giant cells. RANKL is a therapeutic target of osteoporosis and bone metastasis, but the mechanism of the expression is unexplained. To elucidate the mechanism of RANKL expression, we performed this research with next generation sequencing. We will continue this research to discover new therapeutic target for GCTB.